ClinicalTrials.gg
RecruitingNCT06624241Updated Oct 2, 2024

Effectiveness of SRP+ Lipo-curcumin Gel for the Treatment of Stage III Periodontitis.

An interventional study of Lipo-Curcumin gel + SRP and Lipo gel + SRP in Periodontal Diseases, Periodontal Pocket and Periodontal Attachment Loss, sponsored by G. d'Annunzio University. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by G. d'Annunzio University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jun 2024, registered Sep 2024).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Periodontal Diseases with a site in Italy — 18 open to participants now, 20 under way, none of them phase 3. Periodontal Diseases · Italy.

Planned enrollment
14th of 48
40 · median 40
Started
2024
with 5 others
No phase
46 of 72
11 open now
Primary completion
2025-06
later than 5 of 19 live
Registered
56th of 72
by date
Lead sponsor
3 of 72
G. d'Annunzio University

Among the 72 studies in Periodontal Diseases with a site in Italy, this one is the 14th largest by planned enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2024, is one of 46 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 56th registered.

Periodontal Diseases

871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.

Browse Periodontal Diseases studies →

Open to participants now

18 of the 72 studies in Periodontal Diseases with a site in Italy are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Periodontal Diseases with a site in Italy, or all of them as a file.
02

Study summary

The aim of the present study is to clinically and radiographically compare the effectivness of Scaling and Root Plannig (SRP) in association with lipo-curcumin gel (LC) respect SRP+ lipo-gel (L), SRP+ discharged (D) gel and SRP alone.

This study will be designed as a randomized clinical trial of 12-month duration. A total of 40 patients will be recruited and randomly equally distributed into 4 groups: an experimental group treated with SRP + LC, a first control group treated with SRP + L, a second control group treated with SRP+D and a third control group SRP alone.

Each defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following SRP, experimental and control sites will be randomly chosen. The test sites will be t filled with a Lipo-Curcumin gel and sealed with cyanoacrylate. In the first control group the defects will be be filled with a Lipo gel and sealed with cyanoacrylate. In the second control sites he pocket defect will be filled with a discharged gel and sealed with cyanoacrylate, in the third control group SRP alone will be performed.

Pre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.

03

Conditions studied

  • Periodontal Diseases
  • Periodontal Pocket
  • Periodontal Attachment Loss

Keywords

  • Curcumin
  • SRP
  • Liposome
  • Periodontitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of periodontitis stage III (grades A to C)
  • on-smokers or former smokers who quit at least 1 year ago, and had not received any periodontal treatment in the 3 months prior to recruitment
  • FMPS \< 20% at baseline
  • Furcation not involved
  • Not Pregnant or Lactating
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an >7%, rheumatoid arthritis or any form of
  • Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment
  • Chronic intake of NSAIDs or , currently
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Lipo-Curcumin gel + SRP

    After SRP the pocket defect will be filled with a Lipo-Curcumin gel and sealed with cyanoacrylate.

    Procedure: Lipo-Curcumin gel + SRP

  • Active comparator
    Lipo gel + SRP

    After SRP the pocket defect will be filled with a Lipo gel and sealed with cyanoacrylate

    Procedure: Lipo gel + SRP

  • Active comparator
    Discharged Gel + SRP

    After SRP the pocket defect will be filled with a discharged gel and sealed with cyanoacrylate

    Procedure: Discharged Gel + SRP

  • Active comparator
    SRP alone

    SRP alone will be performed.

    Procedure: SRP alone

Interventions

  • ProcedureLipo-Curcumin gel + SRP

    The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo- Curcumin gel. The pocket will be sealed with cyanoacrylate.

  • ProcedureLipo gel + SRP

    The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of Lipo gel. The pocket will be sealed with cyanoacrylate.

  • ProcedureDischarged Gel + SRP

    The pocket defect will be debrided with the use of fine ultrasonic tips and mini hand instruments and will be treated with the application of discharged gel. The pocket will be sealed with cyanoacrylate.

  • ProcedureSRP alone

    The pocket defect will only be debrided with the use of fine ultrasound tips and mini hand instruments and no further treatment will be performed.

06

What researchers measure

Primary outcomes

  1. Pocket Probing Depth (PPD)

    Distance between the gingival margin and the bottom of the pocket.

    Time frame: 12 months

Secondary outcomes

  1. Clinical Attachment Level (CAL)

    Distance between the CEJ and the bottom of the pocket

    Time frame: 12 months

  2. Gingival Recession (GR)

    Distance between the CEJ and the gingival margin.

    Time frame: 12 months

  3. Full Mouth Plaque Score

    Index that evaluates the general presence of bacterial plaque for all teeth. Through the passage of the probe, the presence of plaque deposits is reported for 4 surfaces for each tooth. A ratio is made between the contaminated surfaces and the total surfaces investigated to obtain a percentage value.

    Time frame: 12 months

  4. Full Mouth Bleeding Score

    Index that evaluates the general presence of bleeding for all teeth. Through the insertion of a periodontal probe, the presence of bleeding on probing is signaled for 4 sites for each tooth. A ratio is made between the bleeding sites and the total sites investigated to obtain a percentage value.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • G. d&#39;Annunzio University
    Chieti, CH 66100, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 12 months is close to that.

Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 2, 2024
StartActual
Jun 12, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Sep 2025
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06624241
Lead sponsor
G. d'Annunzio University
Responsible party
Michele Paolantonio (Head of Periodontology, G. d'Annunzio University) — Principal investigator
First posted
Oct 2, 2024
Start date
Jun 12, 2024
Primary completion
Jun 2025 (estimated)
Completion
Sep 2025 (estimated)
Last update
Oct 2, 2024

Study contacts

Michele Paolantonio, DDS, MD
Contact
michelepaolantonio@gmail.com
3395204073
Michele Paolantonio, DDS, MD
study chair · University 'G. D'Annunzio' of Chieti

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion